Application for Regulatory Approvals, Conferences and Presentations, and Enrollment in Clinical Trials - Research Report on Gilead, Alnylam, Omeros, PTC, and Stemline

NEW YORK, September 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Gilead Sciences Inc. (NASDAQ: GILD), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Omeros Corporation (NASDAQ: OMER), PTC Therapeutics, Inc. (NASDAQ: PTCT), and Stemline Therapeutics, Inc. (NASDAQ: STML). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Gilead Sciences Inc. Research Report

On September 11, 2013, Gilead Sciences Inc. (Gilead) announced its submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of idelalisib for the treatment of indolent non-Hodgkin's lymphoma (iNHL). According to Gilead, the data submitted for the NDA support the use of idelalisib for patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. John C. Martin, PhD, Chairman and CEO of Gilead Sciences, stated, "Based on the rate and duration of response observed to date in this highly refractory iNHL patient population, we believe idelalisib could become an important new therapy for patients who have limited treatment options." According to Gilead, Idelalisib is an investigational, targeted, highly selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta:  a protein that is critical for the activation, proliferation and survival of B lymphocytes. The Full Research Report on Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-23/GILD]

--

Alnylam Pharmaceuticals, Inc. Research Report

On September 20, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that its management will give an overview of the Company during the upcoming 20th Annual NewsMakers in the Biotech Industry Conference. Alnylam reported that the presentation will be held at 2:30 p.m. ET, on September 27, 2013 at the Millennium Broadway Hotel in New York City. The Company also stated that a live audio webcast will be available on the News & Investors section of its website. Further, the archive of the presentation will also be available on its website within 48 hours after the conclusion of the event. The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-23/ALNY]

--

Omeros Corporation Research Report

 On September 19, 2013, Omeros Corporation (Omeros) announced the initiation of enrollment in a Phase 2 clinical trial of OMS824, the Company's phosphodiesterase 10 (PDE10) inhibitor. Gilead reported that the trial will evaluate the compound's tolerability, safety, pharmacokinetics, potential interactions with concomitant antipsychotic medications, and a battery of cognitive tests in patients with stable schizophrenia. According to Omeros, PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. The Company stated that in this Phase 2 clinical trial, OMS824 will be administered at various dose levels for two weeks to patients whose antipsychotic medications have been temporarily discontinued or who continue their usual antipsychotic regimen in order to assess the effects of OMS824 as monotherapy and in combination with antipsychotic medications. Gregory A. Demopulos, M.D., Chairman and CEO of Omeros, said, "This Phase 2 trial will provide us with important information on our compound's safety and, potentially, efficacy for additional Phase 2 trials in schizophrenia and Huntington's disease. We look forward to completing the current trial later this year." The Full Research Report on Omeros Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-23/OMER

PTC Therapeutics, Inc. Research Report

On September 18, 2013, PTC Therapeutics, Inc. (PTC) announced that two of its abstracts have been accepted for the 10th European Pediatric Neurology Society Congress (EPNS) in Brussels, Belgium, to be held from September 25, 2013 to September 28, 2013. According to the Company, the two abstracts are: Design of a confirmatory phase 3, multicenter, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy; and Disease-related symptoms and activities of daily living: a novel survey of patients with nonsense mutation Duchenne muscular dystrophy, which will be presented on September 25, 2013 at 13:30 p.m. PTC also informed that it will sponsor a symposium at EPNS titled New perspectives in the management of Duchenne muscular dystrophy on September 25, 2013 from 12:30 p.m. to 13:30 p.m. The Full Research Report on PTC Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-23/PTCT]

--

Stemline Therapeutics, Inc. Research Report

On September 19, 2013, Stemline Therapeutics, Inc. (Stemline) announced that the Company will be participating at the Aegis Capital Corporation 2013 Healthcare Conference to be held at the Encore at Wynn Las Vegas from September 26, 2013 to September 28, 2013. Stemline informed that Ivan Bergstein, M.D., CEO of the Company, will give a presentation at the event on September 28, 2013 at 9:45 a.m. PDT. The Full Research Report on Stemline Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-09-23/STML]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investors' Reports